Engineering a delivery device and development of a novel formulation for chronic obstructive pulmonary disease and cystic fibrosis

点击翻译按钮获取中文摘要

This project will position Australia to become one of the world leaders in the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and other chronic respiratory diseases. The financial burdens of COPD and CF come to at least $900 million a year in Australia alone. These diseases have significant impact on patients and the health system through regular clinical visits, hospitalisation and employment downtime. The global market for the treatment of COPD is currently more than $8 billion and is expected to increase substantially. The positioning of an Australian pharmaceutical company at the forefront of COPD/CF treatment will have significant national benefits for patients, the health system, and research infrastructure in the field.